NCT07766993 · NOT YET RECRUITING

Developing and Testing an AI-Based Cognitive Intervention Program

This trial is testing whether an AI-guided lifestyle program — covering diet, exercise, mental activity, sleep, social connection, and stress — can help protect memory and thinking skills over one year. It also tracks a blood marker called p-tau217, which is linked to Alzheimer's disease. This is a Phase NA study, meaning it is evaluating a behavioral program rather than a drug — it is not yet proven or approved.

You may qualify if

  • Chinese community-dwelling residents aged ≥ 40 years;
  • Cognitive function adequate to cooperate with testing and interventions;
  • No history of major neurological or psychiatric disorders;
  • Not on long-term use of medications known to affect cognitive function significantly ;
  • Possess the basic access and ability to use smartphones or the internet to receive online interventions;
  • Good compliance, with the expected ability to adhere to and complete a 1-year follow-up.

You're excluded if

  • Age \< 40 years;
  • Cognitive function inadequate to cooperate with testing and interventions;
  • History of major neurological disorders (e.g., stroke, Parkinson's disease, brain tumors, epilepsy) or severe psychiatric disorders (e.g., schizophrenia, severe depressive episodes);
  • Currently taking medications known to significantly affect cognitive function (e.g., anticholinergic drugs, certain psychotropic medications);
  • Presence of severe systemic or physical illnesses (e.g., advanced malignancy, severe heart, lung, liver, or kidney failure);
  • Lack of access to smartphones or the internet, rendering the participant unable to receive online interventions;
  • Any other conditions deemed by the investigator as inappropriate for participation in this study.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-08-18

View full record on ClinicalTrials.gov

All APOE4 clinical trials